Accumulating data have demonstrated that MIR31HG modulates downstream target genes at the transcriptional level [27, 28]; however, whether MIR31HG modulates the development of multiple therapy-resistance mechanisms, metastasis, and/or immune evasion in NSCLC via histone epigenetic modification remains unknown. This evidence concerns the gene MIR31HG and non-small cell lung carcinoma.